Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials

Autoimmunity Reviews

Volumn 12, Issue 11, 2013, Pages 1039-1045

  Gleicher, Norbert ^a,b   Elkayam, Uri ^c  

^a CENTER FOR HUMAN REPRODUCTION   (United States)

^b Foundation for Reproductive Medicine   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Autoimmunity; Congenital heart block; Hydroxychloroquine; Intravenous gamma globulin; Pregnancy; Sj gren's syndrome; SSA Ro antibodies; SSB La antibodies; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LA ANTIBODY; PREDNISONE; RO ANTIBODY; STEROID;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARDIOMYOPATHY; CLINICAL EFFECTIVENESS; CONGENITAL HEART BLOCK; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL LITERATURE; MEDLINE; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PLASMAPHERESIS; PROGENY; PUBLICATION; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOIMMUNITY; CHB; CONGENITAL HEART BLOCK; HYDROXYCHLOROQUINE; INTRAVENOUS GAMMA GLOBULIN; IV-IG; PREGNANCY; SJÖGREN'S SYNDROME; SSA/RO ANTIBODIES; SSB/LA ANTIBODIES; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; CLINICAL TRIALS AS TOPIC; HEART BLOCK; HUMANS; INFANT, NEWBORN; MOTHERS; PROSPECTIVE STUDIES; REGISTRIES;

EID: 84881557131     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.04.006     Document Type: Review

References (52)

1. Esscher E., Scott J.S. Congenital heart block and maternal systemic lupus erythematosus. Br Med J 1979, 1:1235-1238.
2. Buyon J., Roubey R., Swersky S., Pompeo L., Parke A., Baxi L., et al. Complete congenital heart block: risk of occurrence and therapeutic approach to prevention. J Rheumatol 1988, 15:1104-1108.
3. Kaaja R., Juljunen H., Ammälä P., Teppo A.M., Kurki P. Congenital heart block: successful prophylactic treatment with intravenous gamma globulin and corticosteroid therapy. Am J Obstet Gynecol 1991, 165:1333-1334.
4. Tunks R.D., Clowse M.E.B., Miller S.G., Branazio L.R., Barker P.C.A. Maternal autoantibody levels in congenital heart block and potential prophylaxis with anti-inflammatory agents. Am J Obstet Gynecol 2013, 208(64):e1-7.
5. Izmirly P.M., Rivera T.L., Buyon J.P. Neonatal lupus syndrome. Rheum Dis Clin North Am 2007, 33:267-285.
6. Llanos C., Friedman D.M., Saxena A., Izmirly P.M., Tseng C.E., Dische R., et al. Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. Rheumatology (Oxford) 2012, 51:1086-1092.
7. 2-glycoprotein I to protect against congenital heart block. Arthritis Rheum 2009, 60:636-638.
8. Buyon J.P., Clancy R.M., Friedman D.M. Autoimmune-associated congenital heart block: integration of clinical and research clues in the management of the maternal/foetal dyad at risk. J Intern Med 2009, 265:653-662.
9. Yoshida H., Iwamoto M., Sakakibara H., Shigeta H., Hirahara F., Sato K. Treatment of fetal congenital complete heart block with maternal administration of beta-sympathomimetics (terbutaline): a case report. Gynecol Obstet Invest 2001, 52:142-144.
10. Kaaja R., Jukunen H. Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Bayon et al. Arthritis Rheum 2003, 48:280-281.
11. Costedoat-Chalumeau N., Amoura Z., Le Thi Hong D., Wechsler B., Vauthier D., Ghillani P., et al. Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis 2003, 62:1010-1012.
12. Aslan E., Tarim E., Kilicdag E., Simsek E. Sjögren syndrome diagnosed in pregnancy: a case report. J Reprod Med 2005, 50:67-70.
13. Hickstein H., Külz T., Claus R., Stange J., Schmidt R. Autoimmune-associated congenital heart block: treatment of the mother with immunoabsorption. Ther Apher Dial 2005, 9:148-152.
14. Yang C.H., Chen J.Y., Lee S.C., Luo S.F. Successful preventive treatment of congenital heart block during pregnancy in women with systemic lupus erythematosus and anti-Sjögren syndrome A/Ro antibody. J Microbiol Immunol Infect 2005, 38:365-369.
15. Izmirly P.M., Costedoat-Chalumeau N., Pisoni C., Khamashta M.A., Kim M.Y., Saxena A., et al. Circulation 2012, 126:76-82.
16. Nguyen T.G., Ward C.M., Morris J.M. To B or not to B cells-mediate a healthy start to life. Clin Exp Immunol 2013, 171:124-134.
17. Brucato A. Prevention of congenital heart block in children of SSA-positive mothers. Rheumatology 2008, 47:iii35-iii37.
18. Gordon P.A. Congenital heart block: clinical features and therapeutic approaches. Lupus 2007, 16:642-646.
19. Gelfand E.W. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012, 367:2015-2025.
20. Miranda-Carús M.E., Boutidir M., Tseng C.E., DiDonato F., Chan E.K., Buyon J.P. Induction of antibodies reactive with SSA/Ro-SSB/La and development of congenital heart block in murine model. J Immunol 1998, 161:5886-5892.
21. Boutjdir M. Molecular and ionic basis of congenital complete heart block. Trends Cardiovasc Med 2000, 10:114-122.
22. Hu K., Qu Y., Yue Y., Boutjdir M. Functional basis of sinus bradycardia in congenital heart block. Circ Res 2004, 94:e32-e38.
23. Suzuki H., Silverman E.D., Wu X., Borges C., Zhao S., Isacovics B., et al. Effect of maternal autoantibodies on fetal conduction: an experimental murine model. Pediatr Res 2005, 57:557-662.
24. Strandberg L.S., Ambrosi A., Jagodic M., Dzikaite V., Janson P., Khademi M., et al. Maternal MHC regulates generation of pathogenic antibodies and fetal MHC-encoded genes determine susceptibility in congenital heart block. J Immunol 2010, 185:3574-3582.
25. Ambrosi A., Dzikaite V., Park J., Strandberg L., Kuchroo V.K., Herlenius E., et al. Anti-Ro52 monoclonal antibodies specific for amino acid 200-239, but not other Rp52 epitopes, induce congenital heart block in a rat model. Ann Rheum Dis 2012, 71:448-454.
26. Ambrosi A., Wahren-Herlenius M. Congenital heart block: evidence for a pathogenic role of maternal autoantibodies. Arthritis Res Ther 2012, 14:208.
27. Lee L.A., Coulter S., Erner S., Chu H. Cardiac immunoglobulin deposition in congenial heart block associated with maternal anti-Ro autoantibodies. Am J Med 1987, 83:793-796.
28. Xia G.Q., Hu K., Boutidir M. Direct inhibition of expressed cardiac l- and t-type calcium channels by IgG from mothers whose children have congenital heart block. Circulation 2001, 103:1599-1604.
29. Restivo M., Kozhevnikov D.O., Boutidir M. Optimal mapping of activation patterns in an animal model of congenital heart block. Am J Physiol Heart Circ Physiol 2001, 280:H1889-1895.
30. Buyon J.P., Clancy R.M. From antibody insult to fibrosis in neonatal lupus- the heart of the matter. Arthitis Res Ther 2003, 5:266-270.
31. Lazzerini P.E., Capecchi P.L., Acampa M., Selvi E., Guideri F., Bisogno S., et al. Arrhythmogenic effects of anti-To/SSA antibodies on the adult heart: more than expected?. Autoimmun Rev 2009, 9:40-44.
32. Lundvig D.M., Immenschuh S., Wagener F.A. Heme oxygenase, inflammation, and fibrosis: the good, the bad, and the ugly?. Front Pharmacol 2012, 3:81.
33. Nelson P.J., Teixeira M.M. Dissection of inflammatory processes using chemokine biology: lessons from clinical models. Immunol Lett 2012, 145:55-61.
34. Gleicher N., Elkayam U. Peripartum cardiomyopathy, an autoimmune manifestation of allograft rejection?. Autoimmun Rev 2009, 8:384-387.
35. Kobayashi R., Mii S., Nakano T., Harada H., Eto H. Neonatal lupus erythematosus in Japan: a review of the literature. Autoimmun Rev 2009, 8:462-466.
36. Carvalheiras G., Faria R., Braga J., Vasconcelos C. Fetal outcome in autoimmune diseases. Autoimmun Rev 2012, 11:A520-A530.
37. Gleicher N., Weghofer A., Barad D.H. Cutting edge assessment of the impact of autoimmunity on female reproductive success. J Autoimmun 2012, 38:J74-80.
38. Gleicher N. Does the immune system induce labor? Lessons from preterm deliveries in women with autoimmune diseases. Clin Rev Allergy Immunol 2010, 39:194-206.
39. Gleicher N., Barad D.H. Gestational dermatosis shortly after implantation associated with parental class II HLA compatibility and maternal immune activation: preliminary report of a prospective case series. Dermatology 2011, 222:206-211.
40. Moorman A.F.M., de Jong F., Denyn M.M.F., Lamers W.H. Development of the cardiac conduction system. Circ Res 1998, 82:629-644.
41. Tunaoglu F.S., Yidirim A., Vurali D. Isolated congenital heart block. Tex Heart Inst J 2010, 37:579-583.
42. ClinicalTrials.gov Identifier: NCT00460928 [accessed 2/1/13]. http://www.ClinicalTrials.gov.com.
43. Friedman D.M., Llanos C., Izmirly P.M., Brock B., Byron J., Copel J., et al. Evaluation of fetuses in the preventive IVIG therapy for congenital heart block (PITCH) study. Arthritis Rheum 2010, 62:1138-1146.
44. Pisoni C.N., Brucato A., Ruffatti A., Espinosa G., Cervera R., Belmonte-Serrano M., et al. Failure of intravenous immunoglobulin to prevent congenital heart block. Findings of a multicenter, prospective, observational study. Arthritis Rheum 2010, 62:1147-1152.
45. Routsias J.G., Kyriakidis N.C., Friedman D.M., Llanos C., Clancy R., Moutsopoulos H.M., et al. Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block. Arthitis Rheum 2011, 63:2783-2789.
46. Palmeira P., Quinello C., Silveira-Less A.L., Zago C.A., Carneiro-Sampaio C.A. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012, 2012. [Article ID 985646].
47. Jordan S.C., Vo A., Tyan D., Toyota M. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Trans Am Clin Climatol Assoc 2006, 117:199-211.
48. Nelson J.L., Hughes K.A., Smith A.G., Nisperos B.B., Branchaud A.M., Hansen J.A. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy induced amelioration of rheumatoid arthritis. N Engl J Med 1993, 329:466-471.
49. ClinicalTrials.gov Identifier: NCT01379573 [accessed 2/1/13]. http://www.ClinicalTrials.gov.com.
50. Izmirly P.M., Kim M.Y., Llanos C., Le P.U., Guerra M.M., Askanase A.D., et al. Evaluation of the risk of anti-SSA/Ro-SSN/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010, 69:1827-1830.
51. Sperber K., Hom C., Chao C.P., Shapiro D., Ash J. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune disease. Pediatr Rheumatol 2009, 7:9.
52. Carbone M.M., Alecsandru D., Castillo-Rama M., Garcia-Segovia A., Gil J., Alonso B., et al. Intravenous immunoglobulin treatment increased live birth rate in a Spanish cohort of women with recurrent reproductive failure and expanded CD56(+) cells. Am J Reprod Immunol 2012, 68:75-84.